Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness

Rituximab (375 mg/m(2)) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A(2) receptor (PLA(2)R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine. Between-treatments interval averaged 17...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMJ Case Rep
Main Authors: Podestà, Manuel Alfredo, Ruggiero, Barbara, Remuzzi, Giuseppe, Ruggenenti, Piero
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7035801/
https://ncbi.nlm.nih.gov/pubmed/31980477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232896
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki